[Research Articles] Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade

This study provides insights into the mechanisms of T-DM1’s therapeutic activity and a rationale for potential therapeutic combination strategies with immunotherapy.

Source: Science Translational Medicine - November 25, 2015 Category: Biomedical Science Authors: Muller, P., Kreuzaler, M., Khan, T., Thommen, D. S., Martin, K., Glatz, K., Savic, S., Harbeck, N., Nitz, U., Gluz, O., von Bergwelt-Baildon, M., Kreipe, H., Reddy, S., Christgen, M., Zippelius, A. Tags: Research Articles Source Type: research